| Business Summary | | Antigenics,
Inc.
is
developing
treatments
for
cancers,
serious
infectious
diseases,
autoimmune
disorders
and
degenerative
disorders,
using
the
Company's
proprietary
technologies
to
program
the
immune
system
and
improve
quality
of
life.
These
products
include
immunotherapeutics
based
on
a
specific
class
of
heat
shock
proteins
(HSPs),
which
activate
powerful
cellular
immune
responses,
and
Stimulon-based
products,
including
QS-21,
which
activates
superior
antibody
responses.
At
year-end
2000,
the
Company
was
evaluating
its
lead
HSP-based
immunotherapeutic,
Oncophage,
in
an
international
multi-center
Phase
III
clinical
trial
in
kidney
cancer,
and
in
five
additional
cancer
indications
in
Phase
II
or
Phase
I/II
trials.
Through
its
internal
programs
and
partnerships,
the
Company
was
also
testing
its
Stimulon-based
products
in
11
Phase
III
and
Phase
II
clinical
trials
for
cancer,
several
infectious
diseases
and
degenerative
disorders. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Antigenics,
Inc.
is
engaged
in
the
discovery
and
development
of
novel
immunotherapeutic
drugs
for
the
treatment
of
life
threatening
and
chronic
medical
conditions.
For
the
six
months
ended
6/30/01,
revenues
totalled
$2.2
million,
up
from
$0.
Net
loss
rose
71%
to
$15.7
million.
Revenues
reflect
product
sales
attributable
to
the
acquisition
of
Aquila
Pharmaceuticals.
Higher
loss
reflects
increased
personnel,
R&D
and
administrative
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Garo Armen, Ph.D., 48 Chairman,
CEO | $500K | Elma Hawkins, Ph.D., 44 Vice
Chairman | 252K | Gamil De Chadarevian, 49 Vice
Chairman, Exec. VP International | -- | Russell Herndon, 42 COO | -- | Neal Gordon, Ph.D., 38 VP
of Operations | 176K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|